Evidence map›Paper›PMID 38086379›Full record

ArticleCell reports. Medicine2023

Econazole selectively induces cell death in NF1-homozygous mutant tumor cells.

Yenal B Lakes, Stefanie L Moye, Juan Mo, Matthew Tegtmeyer, Ralda Nehme, Maura Charlton, Gabrielle Salinas, Renee M McKay, Kevin Eggan, Lu Q Le

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yenal B LakesDepartment of Stem Cell and Regenerative Medicine, Harvard University, Boston, MA, USA.
Stefanie L MoyeDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Medical Scientist Training Program, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Juan MoDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Matthew TegtmeyerStanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Ralda NehmeStanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Maura CharltonDepartment of Stem Cell and Regenerative Medicine, Harvard University, Boston, MA, USA.
Gabrielle SalinasDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Renee M McKayDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kevin EgganDepartment of Stem Cell and Regenerative Medicine, Harvard University, Boston, MA, USA. Electronic address: kevin.eggan@bmrn.com.
Lu Q LeDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; O'Donnell Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: lu.le@utsouthwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous neurofibromas (cNFs) are tumors that develop in more than 99% of individuals with neurofibromatosis type 1 (NF1). They develop in the dermis and can number in the thousands. cNFs can be itchy and painful and negatively impact self-esteem. There is no US Food and Drug Administration (FDA)-approved drug for their treatment. Here, we screen a library of FDA-approved drugs using a cNF cell model derived from human induced pluripotent stem cells (hiPSCs) generated from an NF1 patient. We engineer an NF1 mutation in the second allele to mimic loss of heterozygosity, differentiate the NF1

Indexed as

Induced Pluripotent Stem CellsNeurofibromaNeurofibromatosis 1Skin NeoplasmsAnimalsApoptosisEconazoleHumansMiceUnited StatesEconazolecutaneous neurofibromaeconazolehuman induced pluripotent stem cellsneurofibromatosisNF1Schwann cell precursors

Identifiers

PMID38086379
PMCPMC10772348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.